NUWEHealthcare · Medical Devices

NUWE Stock Forecast: Nuwellis, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026

$0.77

+0.52% on the day

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 15 of 100 as at 12 Sept 2026 — in the weakest quartile.

Market cap

$2.5M

Ticker Nerd rank

15 / 100

Median analyst target

—

Analysts covering

Revenue$2.0M+14.1% y/y

Operating income−$3.2M

Net income−$4.8M

Free cash flow−$3.2M

Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown

Total return, dividends reinvested

+6.0%

−47.7%

YTD

−98.7%

−99.5%

From 52W high

−99.5%

From 52W low

+6.0%

$165

52-week range, adjusted closes · the dot is the last close

Ticker Nerd rank

NUWE stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Nuwellis, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026

15 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size

Growth

Issuance

Quality

Accruals

Revisions

Momentum

Volatility

Value

Size (98): Smaller than most of the companies we track.

Value (0): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

NUWE stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on NUWE, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says1 analysts

0 Buy1 Hold0 Sell

Recent analyst actionsNewest first

Date	Firm	Action	Rating	Target
13 Aug 2024	Roth MKM	Reiterates	Buy	$17
29 July 2024	Roth MKM	Initiates	Buy	—
8 Nov 2023	Ladenburg Thalmann	Downgrade	Neutral	—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. NUWE appears on the weeks it earns a place.

Performance

NUWE vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Nuwellis, Inc. returned −99.5% against +17.5% for the S&P 500, dividends included.

NUWE vs S&P 500, last 12 monthsTotal return, rebased to 100

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

NUWE analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year

Analysts raising

Analysts cutting

Fundamentals

Nuwellis, Inc. (NUWE) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation

Trailing P/E: 0.0×
Price / sales: 0.3×
Price / book: −0.1×
EV / EBITDA: 0.1×

Growth & margins

Revenue growth (YoY): 14.1%
Earnings growth (YoY): 14.1%
Gross margin: 76.1%
Operating margin: −160.9%
Net margin: −125.6%

Returns & dividend

Return on equity: −666.0%
Return on assets: −87.8%
Dividend yield: —

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Nuwellis, Inc. (NUWE) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

Nuwellis, Inc. has a market value of $2.5M and an enterprise value of −$889K.
Revenue in the twelve months to 30 June 2026: $9.0M. The latest quarter grew 14.1% year on year.
Net income over the same four quarters: −$11.3M, a −125.6% net margin.
Diluted earnings per share, trailing twelve months: $−132.69.
Free cash flow in the twelve months to 30 June 2026: −$12.7M.
Shares outstanding: 364,295.
Trailing P/E: 0.0×; forward P/E: −0.3× — the forward figure prices analyst consensus estimates, not reported earnings.
Nuwellis, Inc. employs 38 people — $237K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 13 Sept 2026

Data provided by Twelve Data

Peers

NUWE vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices

Company	Market cap	TKN rank
NUWENuwellis, Inc.	$2.5M	15
XAIRBeyond Air, Inc.	$3.1M	37
AEMDAethlon Medical, Inc.	$2.5M	25
IVFINVO Fertility, Inc.	$2.4M	33
FEEDENvue Medical, Inc.	$3.3M	23
VTAKCatheter Precision, Inc.	$3.3M	26
VVOSVivos Therapeutics, Inc.	$3.7M	32

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Nuwellis, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest NUWE news & analysis

Nuwellis Advances Financial Efficiency Strategy with Improved Gross Margins

GlobeNewsWire · 9 Sept 2026positive

Nuwellis, Inc. highlighted continued progress under its financial efficiency strategy, reporting significant gross margin improvement, sustained product quality and supply performance, and further optimization of its cost structure for patients with cardiorenal conditions.

Why it matters — A NUWE watcher would care because improved gross margins and cost optimization signal stronger financial efficiency and operational performance for the company.

Nuwellis Expands Critical Care Portfolio Through Strategic Commercial Agreement with Atrility Medical

GlobeNewsWire · 25 Aug 2026positive

Nuwellis entered a strategic commercial agreement with Atrility Medical that expands its pediatric and critical care portfolio and establishes a milestone-based pathway toward U.S. distribution.

Why it matters — A Nuwellis watcher would care because this agreement broadens the company's critical care offerings and creates a defined route to U.S. commercial availability through specified milestones.

Nuwellis, Inc. (NUWE) Q2 2026 Earnings Call Prepared Remarks Transcript

Seeking Alpha · 13 Aug 2026neutral

Nuwellis, Inc. held its Q2 2026 earnings call, and Seeking Alpha published the prepared remarks transcript from the event.

Why it matters — Earnings call transcripts provide direct insight into the company's operational performance and management's commentary, which can influence investor perception of Nuwellis.

Nuwellis Reports Second Quarter 2026 Financial Results and Business Highlights Focused on Double Digit Revenue Growth and Expanded Gross Margin

GlobeNewsWire · 13 Aug 2026positive

Nuwellis, Inc. reported its financial results for the three and six months ended June 30, 2026, highlighting double-digit revenue growth and an expanded gross margin. The company also noted that a recent capital raise and warrant exercises extend its cash runway through the second quarter of 2027, with a conference call scheduled for 9:00 a.m. Eastern time.

Why it matters — A Nuwellis watcher would care because the results confirm double-digit revenue growth and improved gross margin, while the extended cash runway through Q2 2027 provides financial visibility for the company's cardiorenal-focused operations.

Nuwellis Strengthens Product Development Organization with Appointment of Dale Brady as Principal R&D Engineer

GlobeNewsWire · 6 Aug 2026positive

Nuwellis, Inc. announced the appointment of Dale Brady as Principal R&D Engineer. Brady brings more than 25 years of medical device leadership experience in research and development, operations, manufacturing, quality systems and commercialization, with a record of advancing products from concept through commercial launch.

Why it matters — The appointment strengthens Nuwellis' product development organization with an experienced R&D leader who has a track record of moving medical devices from concept to market.

FAQ

Frequently asked questions about NUWE stock

Is NUWE stock a buy right now?

Of the 1 analysts covering Nuwellis, Inc., 0 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Nuwellis, Inc. 15 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank NUWE?

As at 12 Sept 2026, Nuwellis, Inc. ranks 15 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (98 of 100).

What is the NUWE stock forecast for 2030?

No analyst covering Nuwellis, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for NUWE are extrapolating price history, which says nothing about the business.

How has NUWE stock performed over the past year?

Nuwellis, Inc. returned -99.5% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Nuwellis, Inc. do?

Nuwellis, Inc. is a medical technology company focused on fluid management for patients with cardiorenal and cardiovascular conditions.

What is the latest news on NUWE?

The most recent item we track (GlobeNewsWire, 9 Sept 2026): "Nuwellis Advances Financial Efficiency Strategy with Improved Gross Margins". Nuwellis, Inc. highlighted continued progress under its financial efficiency strategy, reporting significant gross margin improvement, sustained product quality and supply performance, and further optimization of its cost structure for patients with cardiorenal conditions.

Company

About Nuwellis, Inc.

Nuwellis, Inc. is a medical technology company focused on fluid management for patients with cardiorenal and cardiovascular conditions. The company develops and commercializes ultrafiltration therapy systems, including the Aquadex SmartFlow and Aquadex FlexFlow platforms, which are designed to remove excess fluid when conventional medical management, such as diuretics, is not sufficient. Its devices are used in hospital settings for adult and pediatric patients, supporting clinicians in acute and critical care environments. Nuwellis serves the healthcare market through products intended to address fluid overload, a condition associated with heart failure and related complications. Headquartered in Eden Prairie, Minnesota, Nuwellis concentrates on specialized medical devices that help providers manage complex fluid-balance needs across a range of clinical settings.

CEO Mr. Michael Kendrick McCormick · 38 employees · United States · https://www.nuwellis.com